Log in

NASDAQ:ARVN - Arvinas Stock Price, Forecast & News

$37.76
-1.16 (-2.98 %)
(As of 12/6/2019 01:10 AM ET)
Today's Range
$37.16
Now: $37.76
$39.04
50-Day Range
$15.39
MA: $27.07
$39.02
52-Week Range
$10.19
Now: $37.76
$39.33
Volume172,800 shs
Average Volume207,576 shs
Market Capitalization$1.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.73
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone203-535-1456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.32 million
Book Value$4.22 per share

Profitability

Net Income$-41,480,000.00
Net Margins-157.34%

Miscellaneous

Employees83
Market Cap$1.27 billion
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.


Arvinas (NASDAQ:ARVN) Frequently Asked Questions

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

How were Arvinas' earnings last quarter?

Arvinas Inc (NASDAQ:ARVN) released its earnings results on Monday, November, 4th. The company reported $0.21 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.67. The firm had revenue of $30.05 million for the quarter, compared to the consensus estimate of $11.42 million. Arvinas had a negative net margin of 157.34% and a negative return on equity of 31.57%. View Arvinas' Earnings History.

When is Arvinas' next earnings date?

Arvinas is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Arvinas.

What price target have analysts set for ARVN?

9 brokers have issued 12 month target prices for Arvinas' shares. Their forecasts range from $22.00 to $50.00. On average, they expect Arvinas' share price to reach $36.75 in the next twelve months. This suggests that the stock has a possible downside of 2.7%. View Analyst Price Targets for Arvinas.

What is the consensus analysts' recommendation for Arvinas?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arvinas.

Has Arvinas been receiving favorable news coverage?

Media stories about ARVN stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arvinas earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Arvinas.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,740,000 shares, an increase of 141.3% from the October 31st total of 721,200 shares. Based on an average trading volume of 269,600 shares, the short-interest ratio is currently 6.5 days. Approximately 10.7% of the company's stock are sold short. View Arvinas' Current Options Chain.

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Who are Arvinas' key executives?

Arvinas' management team includes the folowing people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
  • Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
  • Dr. Ian Taylor, Chief Scientific Officer (Age 56)
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Andrew Crew, Chief Technology Officer (Age 54)

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (6.21%), Point72 Asset Management L.P. (1.41%), State Street Corp (1.02%), Barclays PLC (0.26%), Chicago Equity Partners LLC (0.09%) and California State Teachers Retirement System (0.08%). Company insiders that own Arvinas stock include Bradley Albert Margus, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View Institutional Ownership Trends for Arvinas.

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Point72 Asset Management L.P. and Matisse Capital. Company insiders that have sold Arvinas company stock in the last year include Ian Taylor, Sean A Cassidy and Ventures Iii LP 5Am. View Insider Buying and Selling for Arvinas.

Which major investors are buying Arvinas stock?

ARVN stock was bought by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, Chicago Equity Partners LLC, Squarepoint Ops LLC, Millennium Management LLC, Kellogg W K Foundation Trust, Metropolitan Life Insurance Co NY and Strs Ohio. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy and Timothy M Shannon. View Insider Buying and Selling for Arvinas.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $37.76.

How big of a company is Arvinas?

Arvinas has a market capitalization of $1.27 billion and generates $14.32 million in revenue each year. The company earns $-41,480,000.00 in net income (profit) each year or ($25.45) on an earnings per share basis. Arvinas employs 83 workers across the globe.View Additional Information About Arvinas.

What is Arvinas' official website?

The official website for Arvinas is http://www.arvinas.com/.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]


MarketBeat Community Rating for Arvinas (NASDAQ ARVN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote "Outperform" if you believe ARVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel